These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7819543)
1. 'Priming' enhances the relationship of striatal L-dopa concentration to behavior. Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ Neuroreport; 1994 Aug; 5(13):1665-9. PubMed ID: 7819543 [TBL] [Abstract][Full Text] [Related]
2. Early L-dopa treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation. Carey RJ; Pinheiro-Carrera M; Tomaz C; Huston JP Brain Res; 1994 Sep; 658(1-2):145-54. PubMed ID: 7834335 [TBL] [Abstract][Full Text] [Related]
3. L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism. Carey RJ; Dai H; Huston JP; Pinheiro-Carrera M; Schwarting RK; Tomaz C Brain Res Bull; 1995; 37(3):295-9. PubMed ID: 7627573 [TBL] [Abstract][Full Text] [Related]
4. L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation. Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ Life Sci; 1994; 55(13):991-7. PubMed ID: 8084215 [TBL] [Abstract][Full Text] [Related]
5. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats. Ciesielska A; Sharma N; Beyer J; Forsayeth J; Bankiewicz K PLoS One; 2015; 10(4):e0122708. PubMed ID: 25860990 [TBL] [Abstract][Full Text] [Related]
6. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation. Brannan T; Prikhojan A; Yahr MD Brain Res; 1998 Feb; 784(1-2):148-53. PubMed ID: 9518585 [TBL] [Abstract][Full Text] [Related]
7. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine. Dethy S; Laute MA; Damhaut P; Goldman S J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935 [TBL] [Abstract][Full Text] [Related]
8. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Carey RJ Brain Res; 1991 Dec; 568(1-2):205-14. PubMed ID: 1814568 [TBL] [Abstract][Full Text] [Related]
9. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. II. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum. Sato S; Koitabashi T; Koshiro A Biol Pharm Bull; 1994 Dec; 17(12):1622-9. PubMed ID: 7735207 [TBL] [Abstract][Full Text] [Related]
11. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301 [TBL] [Abstract][Full Text] [Related]
12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
13. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons. Van De Witte SV; Groenewegen HJ; Voorn P Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728 [TBL] [Abstract][Full Text] [Related]
14. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Zeng BY; Jolkkonen J; Jenner P; Marsden CD Neuroscience; 1995 May; 66(1):19-28. PubMed ID: 7637869 [TBL] [Abstract][Full Text] [Related]
15. The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study. Gnanalingham KK; Robertson RG Brain Res; 1994 Mar; 640(1-2):185-94. PubMed ID: 8004447 [TBL] [Abstract][Full Text] [Related]
16. PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease. Nichols NF; Cimini MG; Haas JV; Staton BA; Tedroff J; Svensson KA Neuropharmacology; 2002 Oct; 43(5):817-24. PubMed ID: 12384167 [TBL] [Abstract][Full Text] [Related]
17. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. Hossain MA; Weiner N J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772 [TBL] [Abstract][Full Text] [Related]
18. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306 [TBL] [Abstract][Full Text] [Related]
20. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Napolitano A; Zürcher G; Da Prada M Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]